

A Study of Tulumimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Last Update: May 15, 2025

A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

ClinicalTrials.gov Identifier:

[NCT04104776](#)

Novartis Reference Number:CDZR123A02101

[See if you Pre-qualify](#)

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulumimetostat as a monotherapy in patients with advanced solid tumors and lymphomas. The study is divided into Phase 1 and Phase 2. In Phase 1 and the Phase 2 expansion (M1 to M7), patients are non-randomized. In Phase 2 optimization, patients in Cohort M2 and M3 (Stage 2a and 2b) and Cohort M8 (Part 2) are randomized.

Phase 1 of the study is composed of a Tulumimetostat Dose Escalation period in patients with advanced tumors and aims to determine maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of Tulumimetostat as monotherapy in patients with advanced tumors.

Phase 2 of the study is planned to evaluate safety and tolerability and antitumor activity of Tulumimetostat in six disease-specific cohorts (M1 to M6). Patients in Cohorts M1, M2, M3, M5, and M6 will be enrolled at 10 to 29 patients per cohort, using a Simon 2-stage design. Cohort M4 will enroll up to 20 patients with lymphoma in a single-stage.

The primary aim of Phase 2 part of the study is to evaluate the antitumor activity of Tulumimetostat, and characterize the safety and tolerability of Tulumimetostat as monotherapy in patients with selected tumors.

In Phase 2, two additional doses are planned to be evaluated in cohorts M2 and M3 in 2 stages: Stage 2a and Stage 2b. In Stage 2a approximately 20 patients will be enrolled per cohort and will be randomized 1:1 to receive 2 prespecified dose levels of Tulumimetostat once daily. When protocol criteria for initiating Stage 2b will be fulfilled after completion of Stage 2a, then Stage 2b will be opened for enrolment of additional 10 patients in one or both dose arms in each of the two cohorts. Thus, up to 40 patients per cohort (M2 and M3) could be enrolled.

The study will explore the Tulumimetostat in anti-tumor activity and effect of food on pharmacokinetics of Tulumimetostat in patients with ARID1A WT endometrial carcinoma (Cohort M7) and safety and anti-tumor activity of Tulumimetostat in combination with enzalutamide in patients with mCRPC (Cohort M8).

In Cohort M8 Part 1, the safety and tolerability of Tulumimmetostat in and enzalutamide combination will be evaluated in patients with mCRPC. The M8 Part 1 dose escalation incorporates combination of Tulumimmetostat in at escalating provisional doses with enzalutamide.

In Cohort M8 Part 2, the safety, tolerability and preliminary antitumor activity of Tulumimmetostat at a RP2D in combination with enzalutamide will be further evaluated in patients with mCRPC.

Condition

Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer

Phase

Phase1, Phase2

Overall Status

Recruiting

Number of Participants

275

Start Date

Sep 18, 2019

Completion Date

Feb 27, 2030

Gender

All

Age(s)

18 Years - (Adult, Older Adult)

Interventions

Drug

Enzalutamide

Enzalutamide dosed once per day orally in 28 day cycles

Drug

Tulumimmetostat

Tulumimmetostat dosed once per day orally in 28 day cycles

Eligibility Criteria

Key Inclusion Criteria:

* Eligible Phase 1 patients are adults who have a confirmed locally advanced or metastatic tumors (solid tumors or lymphoma) that have relapsed following standard therapy or progressed through standard therapy or who have a disease for which no standard effective therapy exists.

* Eligible Phase 2 patients in cohorts M1 to M3 are adults who are known to have the ARID1A mutation by next-generation sequencing (NGS) testing; have measurable disease per Response Evaluation Criteria in Solid Tumors 1.1 and who have confirmed relapsed urothelial or other advanced/metastatic solid tumors (M1),

ovarian clear cell carcinoma (M2), or endometrial carcinoma (M3).

- * Eligible Phase 2 patients in Cohort M4 are adults who have either relapsed or refractory PTCL (at least 10 patients) or DLBCL (up to 10 patients), including patients with documented GCB DLBCL with EZH2 hotspot mutation. Patients with PTCL must have at least 1 prior line of therapy and patients with DLBCL must have at least 2 prior lines of standard therapy; and are not considered candidates to receive CAR-T or ASCT therapy.
- * Eligible Phase 2 patients in Cohort M5 are adults who are known to have the BAP1 loss, have malignant pleural or peritoneal mesothelioma, and have progressed on at least 1 prior line of active therapy.
- * Eligible Phase 2 patients in Cohort M6 are adults who have mCRPC with measurable soft tissue disease with CT scan as defined by PCWG3 criteria, have baseline testosterone levels ≤ 50 ng/dL (≤ 2.0 nM) and have surgical or ongoing medical castration and who have progressed on at least 1 androgen-receptor signaling inhibitor and at least 1 taxane-based chemotherapy (cabazitaxel, France only).
- * Eligible Phase 2 patients in Cohort M7 are adults with recurrent, advanced ARID1A WT endometrial carcinoma confirmed by NGS testing and have measurable disease per Response Evaluation Criteria in Solid Tumors 1.1. Patients will be enrolled with maximum up to 2 prior lines of systemic therapy for treating endometrial carcinoma that must include at least one treatment line with systemic platinum-based chemotherapy in advanced/ recurrent disease setting, and anti-programmed cell death protein 1 (PD-1)/ anti-programmed death-ligand 1 (PD-L1) therapy, either in combination or separately, unless these are contraindicated or are not locally accessible.
- * Eligible Part 1 and Part 2 patients in Cohort M8 are adults who have mCRPC with measurable soft tissue disease as per PCWG3 criteria, have baseline testosterone levels ≤ 50 ng/dL (≤ 2.0 nM), have surgical or ongoing medical castration or hormone sensitive prostate cancer (HSPC) disease stage. In addition, Eligible part 1 patients in Cohort M8 may have received abiraterone treatment in mCRPC while eligible part 2 patients in Cohort M8 must have received abiraterone treatment in mCRPC. In addition, only for M8 Part 1: Patients may have received no more than one previous regimen of taxane-based chemotherapy in mCRPC or HSPC setting. For M8 Part 2: Patients may have received no more than one previous regimen of taxane-based chemotherapy in HSPC setting. Patients for both M8 Part 1 and M8 Part 2 must have evidence of prostate cancer progression (per PCWG3) and must have ongoing ADT (androgen deprivation therapy) with a GnRH analogue, antagonist or bilateral orchiectomy (i.e., surgical or medical castration).
- * All patients will have Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 and adequate organ function.

Key Exclusion Criteria:

1. Medical Conditions

- * Previous solid organ or allogeneic hematopoietic cell transplantation (HCT).
- * Known symptomatic untreated brain metastases. Patients with central nervous system (CNS) metastases must have stable neurologic status following local therapy for at least 4 weeks on a stable or decreasing dose of steroids (≤ 10 mg daily prednisone or equivalent). Patients in the M4 lymphoma cohort are excluded if they have known CNS involvement by lymphoma.
- * Clinically significant cardiovascular disease, including:
 - * Myocardial infarction or stroke within 3 months (6 months for M8 cohort) prior to Day 1 of treatment.
 - * Unstable angina within 3 months (6 months for M8 cohort) prior to Day 1 of treatment.
 - * Congestive heart failure or cardiomyopathy with New York Heart Association (NYHA) Class 3 or 4.
 - * History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes).
 - * Uncontrolled hypertension despite 2 concomitant antihypertensive therapies.
- * For Cohorts M1-M6: QT interval corrected by the Fridericia correction formula (QTcF) > 480 msec on the Screening ECG.

- * For Cohorts M7 and M8: QTcF interval $\geq$ 450 msec at screening.
- * Major surgery within 4 weeks before starting study drug or not recovered from any effects of prior major surgery (uncomplicated central line placement or fine needle aspirate are not considered major surgery).
- * Gastrointestinal disorders that may significantly interfere with the absorption of the study medication, such as ulcerative colitis, malabsorption syndrome, refractory nausea and vomiting, biliary shunt, significant bowel resection.
- * Uncontrolled active infection requiring intravenous antibiotic, antiviral, or antifungal medications within 14 days before the first dose of study drug. Controlled infections on concurrent antimicrobial agents and antimicrobial prophylaxis per institutional guidelines are acceptable.
- * Suspected pneumonitis or interstitial lung disease (confirmed by radiography or CT) or a history of these conditions.
- * History of a concurrent or second malignancy except for certain adequately treated cancers such as local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease, adequately treated Stage 1 or 2 cancer currently in complete remission, or any other cancer in complete remission for $\geq$ 3 years. Patients with a history of T-cell lymphoblastic lymphoma or T-cell lymphoblastic leukemia are not eligible.
- * Current known active or chronic infection with HIV, hepatitis B, or hepatitis C. Screening for these viruses is not required unless there is a past history or current suspicion of viral hepatitis.
- * Clinically active or symptomatic viral hepatitis or chronic liver disease.
- * Unstable or severe uncontrolled medical condition or any important medical or psychiatric illness or abnormal laboratory finding that would increase the risk to the patient associated with participation in the study.
- * For Cohort M7 Only: Patients not willing to or cannot remain fasted due to a medical condition for 2 hours before and 1 hour after dose administration.

2. Prior/Concomitant Therapy:

* Prior Anticancer Treatment:

* Systemic Anticancer Treatment: Patients must not have received chemotherapy, targeted therapy, small molecules, antibodies, investigational anticancer therapy, or other anticancer therapeutics (except gonadotropin-releasing hormone analogues) within 4 weeks (or 5 half-lives, whichever is shorter) before the first dose of the study drug. For nitrosoureas or mitomycin C, a 6-week washout is required. For prior PD-1 or PD-L1 therapy, a washout period of at least 4 weeks is acceptable. All toxicities from prior therapies must have resolved to Grade 1 or less, except for endocrinopathies requiring medication, neuropathy, and alopecia, which must have resolved to Grade 2 or less.

* EZH2 Inhibitor: Previous treatment with an EZH2 inhibitor is not allowed.

* Radiation Therapy: Patients must not have received radiation therapy (including radiofrequency ablation) within 4 weeks before the first dose of the study drug. However, a single fraction of radiotherapy for palliation confined to one field is permitted within 1 week prior to Day 1 of treatment.

* Stereotactic Body Radiation Therapy: Patients must not have received this therapy within 2 weeks before the first dose of the study drug.

* Chemoembolization or Radioembolization: Patients must not have received these treatments within 4 weeks before the first dose of the study drug.

* Concomitant Medication:

* CYP3A4/5 Inducers or Inhibitors: Patients must not take strong CYP3A4/5 inducers or inhibitors (except enzalutamide in Cohort M8) within 7 days or 5 times the reported half-life of the CYP3A4/5 inhibitor or inducer (whichever is longer) prior to the first dose of the study drug and for the duration of the study.

3. Other Exclusions

* General Exclusions:

* **Pregnancy and Breastfeeding:** Patients who are breastfeeding, pregnant (as confirmed by a serum β -hCG pregnancy test within 72 hours prior to the first dose of the study drug), or planning to conceive or father children during the trial and for 183 days after the last dose of the study drug are excluded. Women of nonchildbearing potential (post-menopausal for more than 1 year or surgically sterilized) do not require a serum pregnancy test. A highly sensitive urine test can be used if a serum test is not appropriate. Female patients with false-positive β -hCG values may be enrolled with written consent from the Sponsor's Medical Monitor after pregnancy has been excluded.

* **Compliance:** Patients who are unwilling or unable to comply with the study protocol or requirements are excluded.

* **Additional Exclusions for Cohort M6 (mCRPC) Only:**

* **Bone-only Disease:** Patients with bone-only disease without nodal disease and no evidence of visceral spread are excluded.

* **Structurally Unstable Bone Lesions:** Patients with bone lesions that are structurally unstable and concerning for impending fracture are excluded.

* **Herbal Products:** Patients using herbal products that may decrease prostate-specific antigen (PSA) levels within 4 weeks prior to Day 1 of treatment and during the study are excluded.

* **Prostate Cancer Treatments:** Patients who have received the following treatments for prostate cancer within the specified timeframes prior to Day 1 of treatment are excluded:

1. First-generation androgen receptor antagonists (e.g., bicalutamide, nilutamide, flutamide) within 4 weeks.

2. 5 α reductase inhibitors, ketoconazole, estrogens (including diethylstilbestrol), or progesterones within 2 weeks.

* **Planned Palliative Procedures:** Patients with planned palliative procedures for alleviation of bone pain, such as radiation therapy or surgery, are excluded.

4. **Additional Exclusion Criteria for Cohort M8 (DZR123 and Enzalutamide Combination in mCRPC) only:**

* **Biochemical recurrence/prostate-specific antigen (PSA)-only disease.**

* **Prior Enzalutamide Treatment:**

* **For M8 Part 1:** Patients who have received prior enzalutamide.

* **For M8 Part 2:** Patients who have received prior enzalutamide, apalutamide, darolutamide, or any other investigational androgen receptor pathway inhibitor (ARPi).

* **Herbal Products:** Use of herbal products that may decrease PSA levels within 4 weeks prior to Day 1 of treatment and during the study.

* **Planned Palliative Procedures:** Planned palliative procedures for alleviation of bone pain, such as radiation therapy or surgery.

* **Investigational Agents:** Treatment with any investigational agent within 4 weeks before Day 1 of M8 Part 1 or M8 Part 2.

* **Bone Marrow Irradiation:** Prior irradiation to more than 25% of the bone marrow.

* **Gastrointestinal Conditions:** Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease, or previous gastric resection or lap band surgery. Gastroesophageal reflux disease under treatment with proton pump inhibitors is allowed.

* **Seizure History:** History of seizure, loss of consciousness, or transient ischemic attack within 12 months of study entry, or any condition that may predispose to seizure (e.g., stroke, brain arteriovenous malformation, head trauma, underlying brain injury).

Bergonie Institute

Recruiting

Bordeaux,33000,France

Antoine Italiano

Laura Wanner

Phone: +33 (556) 333-282

Email: l.wanner@bordeaux.unicancer.fr

Nord Laennec Hospital

Recruiting

Saint-Herblain,44800,France

Thomas Gastinne

Helene Godet

Phone: +33 (0) 2 40 16 56 98

Email: helene.godet@chu-nantes.fr

Nantes University Hospital Center - Hotel Dieu Hospital (Satellite)

Recruiting

Nantes,44093,France

Thomas Gastinne

Tiphaine Chiron

Phone: +33 (0) 240 08 40 30

Email: tiphaine.chiron@chu-nantes.fr

Claire Peluchon

Phone: +33 (0) 2 53 48 22 43

Email: claire.peluchon@chu-nantes.fr

Strasbourg Europe Institut of Cancerology

Recruiting

Strasbourg,67200,France

Lauriane Eberst

Lucie-Anne Casper

Phone: +33 (0) 368767150

Email: a.casper@icans.eu

Oscar Lambret Center

Recruiting

Lille,59020,France

Cyril Abdeddaim

Solaya Chalal

Phone: +33 (0) 3 20 29 56 38

Email: s-chalal@o-lambret.fr

Gustave Roussy

Recruiting

Villejuif,94805,France

Mariem Labiadh

Phone: +33 (0) 142 11 61 72

Email: Mariem.LABIADH@gustaveroussy.fr

Vincent Ribrag, MD

Leon Berard Center

Recruiting

Lyon,69373,France

Emilie Repetto

Phone: +33 (0) 4 78 78 20 62

Email: emilie.repetto@lyon.unicancer.fr

Mehdi Brahmi

Italy

Irccs University Hospital of Bologna

Recruiting

Bologna,40138,Italy

Silvia Corazza

Phone: 39 051 214 3231

Email: silvia.corazza3@unibo.it

Pier Luigi Zinzani, MD

Gruppo Humanitas - Humanitas Research Hospital - Cancer Center

Recruiting

Rozzano,20089,Italy

Carmelo Carlo-Stella

Laura Paladini

Phone: 39 02 8224 5954

Email: laura.paladini@cancercenter.humanitas.it

National Cancer Institute, IRCCS

Recruiting

Milan,20133,Italy

Federica Mogavero

Email: Federica.Mogavero@istitutotumori.mi.it

Mara Mantiero

European Institute of Oncology (IEO), IRCCS

Recruiting

Milan,20141,Italy

Beatrice Rizzoli

Phone: +39 (029) 4372-183

Email: Beatrice.Rizzoli@ieo.it

Nicoleta Colombo

University Polyclinic Foundation "Agostino Gemelli" - IRCCS

Recruiting

Rome,00168,Italy

Giulia Ferrara

Phone: +39 (06) 30158 545

Email: giulia.ferrera@policlinicogemelli.it

Vanda Salutari

Korea, Republic of

Asan Medical Center

Recruiting

Seoul,05505,Korea, Republic of

Lee Jin Hwa

Phone: [82-22-045-3855](tel:82-22-045-3855)

Email: ljh3531@amc.seoul.kr

Yong-Man Kim

Gachon University Gil Medical Center

Recruiting

Incheon,21565,Korea, Republic of

Lee Kwang-Beom

Yoon Jiae

Phone: [010-7583-3119](tel:010-7583-3119)

Email: 76344@ncc.re.kr

Gangnam Severance Hospital

Recruiting

Seoul,06273,Korea, Republic of

Jae-Hoon Kim

Mina Jang

Phone: [8210-8737-0811](tel:8210-8737-0811)

Email: mnj2023sc@yuhs.ac

Keimyung University - Dongsan Medical Center

Recruiting

Daegu,42601,Korea, Republic of

Cho Chi-Heum

Cho SeHee

Phone: 82 (53) 258 6679

Email: cjjs200400@gmail.com

Seoul National University Hospital

Recruiting

Seoul,03080,Korea, Republic of

Jae-Weon Kim

Kim So Jeong

Phone: 010-9266-2851

Email: snu_sojeong@snu.ac.kr

National Cancer Center

Recruiting

Goyang-si,10408,Korea, Republic of

Heo Suyeon

Phone: 82-31-920-0859

Email: 76656@ncc.re.kr

Lim Myong Cheol

Severance Hospital, Yonsei University Health System

Recruiting

Seoul,03722,Korea, Republic of

Lee Jihyun

Phone: 82 22-228-2759

Email: HMJH24@yuhs.ac

Lee Jung-Yun

Poland

Polish Mother's Memorial Hospital-Research Institute

Recruiting

Lodz,93-338,Poland

Ewa Kalinka

Marta Grubiak

Phone: 0048 792 206 646

Email: grubiak.marta@gmail.com

Maria Sklodowska-Curie - National Research Institute of Oncology

Recruiting

Warsaw, 02-781, Poland

Jan Walewski, MD

Anna Pich

Phone: 0048 22 546 2223

Email: Anna.Pich@nio.gov.pl

University Teaching Hospital in Poznan, Department of Gynecologic Oncology

Recruiting

Poznan, 60-569, Poland

Krzysztof Balcerzak

Phone: 0048 574432284

Email: kbalcerzak@ump.edu.pl

Radosław Madry

Medical Center Pratia Poznan

Recruiting

Skorzewo, 60-185, Poland

Hubert Kondarewicz

Phone: 0048 512 491 461

Email: hubert.kondarewicz@pratia.com

Marek Kotlarski, MD

University Teaching Centre, Early Clinical Trials Unit

Recruiting

Gdansk, 80-214, Poland

Rafał Dziadziuszko

Zofia Specht-Szwoch

Phone: 48 58 584 44 17
Email: zspecht@uck.gda.pl

Spain

University Clinic of Navarra - Madrid

Recruiting

Madrid,28027,Spain

Antonio Gonzalez Martin

Maria Aleman Ramos

Phone: +34 (91) 353 1920 Ext 7539
Email: maleman@unav.es

University Hospital Complex of Santiago (CHUS)

Recruiting

Santiago De Compostela,15706,Spain

Maria Teresa Curiel Garcia

Carolina Garcia Martinez

Phone: +34981950512/ +3498195567
Email: cgarciamartinez.enf@gmail.com

University Hospital Son Espases

Recruiting

Palma De Mallorca,07120,Spain

Neomi Ceron Pisa

Phone: +34 871 20 61 30
Email: noemi.ceron@ssib.es

Jesus Alarcon Company

University Hospital Virgen del Rocio (HUVR)

Recruiting

Seville,41013,Spain

Alejandro Falcon Gonzalez

Montserrat Dominguez

Phone: +34 (696) 635-551

Email: montse.oncologiahuvr@gmail.com

University Hospital Vall d'Hebron

Recruiting

Barcelona,08035,Spain

Alba Meire

Phone: (+34)93 274 60 00 4691

Email: ameire@vhio.net

Albert Meire (Oncology)

Phone: +34 93 274 60 00

Email: ameire@vhio.net

Ana Oaknin

University Clinic of Navarra - Pamplona

Recruiting

Pamplona,31008,Spain

Antonio Gonzalez Martin

Mercedes Egana Gorraiz

Phone: +34 (948) 255 400 Ext 2733

Email: megana@unav.es

University Hospital 12 de Octubre

Recruiting

Madrid,28041,Spain

Irene Pascual

Phone: +34 913908626

Email: ipascualsr.imas12@h12o.es

Luis Manso Sanchez

Valencia Oncology Institute (IVO)

Recruiting

Valencia,46009,Spain

Ignacio Romero Noguera

Lidia Riquelme

Phone: [+34 663224865](tel:+34663224865)

Email: datamanager3@fincivo.org

University Clinical Hospital of Salamanca

Recruiting

Salamanca,37007,Spain

Alejandro Martin Garcia-Sancho, MD, PhD

Manuel Delgado Criado

Phone: [+34 \(923\) 291 316](tel:+34923291316)

Email: mdelgadocri@saludcastillayleon.es

University Hospital Quiron Madrid

Recruiting

Madrid,28223,Spain

Rebeca Sanchez

Phone: [+34 914521900](tel:+34914521900) (ext. 38901)

Email: rsanchez@nextoncology.eu

Valentina Boni

University Hospital of Girona Dr. Josep Trueta

Recruiting

Girona,17007,Spain

Maria Pilar Barretina Ginesta

Nuria Martin

Phone: [+34 972 75 49 53](tel:+34972754953)

Email: nmartin@iconcologia.net

United Kingdom

Royal United Hospital

Recruiting

Bath,Ba1 3ng,United Kingdom

Samantha Curtis

Phone: 01225 824288

Email: samantha.curtis@nhs.net

Rebecca Bowen

Royal Marsden Hospital - Sutton

Recruiting

Sutton, Sm2 5pt, United Kingdom

Fiona Williams

Phone: 442031865362

Email: Fiona.Williams@rmh.nhs.uk

Susana Banerjee

University Hospitals of Leicester NHS Trust

Recruiting

Leicester, Le5 4pw, United Kingdom

Harriet Walter, MD

Sarah Porter

Phone: 0116 258 7598

Email: sarah.porter@uhl-tr.nhs.uk

Musgrove Park Hospital

Recruiting

Taunton, Ta1 5da, United Kingdom

Emma Cattell

Tamlyn Russel

Phone: 01823 342582

Email: Tamlyn.Russell@SomersetFT.nhs.uk

Royal Marsden Hospital - London

Recruiting

London, Sw3 6jj, United Kingdom

Susanna Banerjee

Imperial College Healthcare NHS Trust

Recruiting

London, Sw7 2az, United Kingdom

Jonathan Krell

Lauren Holt

Phone: [0208 383 1366](tel:02083831366)

Email: lauren.holt9@nhs.net

The Christie NHS Foundation Trust, Department of Medical Oncology

Recruiting

Manchester, M20 4bx, United Kingdom

Andrew Clamp

United States

Hackensack University Medical Center

Recruiting

Hackensack, New Jersey, 07601, United States

Martin Gutierrez, MD

Celina Joco

Phone: [551-996-8170](tel:5519968170)

Email: Celina.Joco@hmn.org

Dana Farber Cancer Institute

Recruiting

Boston, Massachusetts, 02215-5450, United States

Alok Tewari, MD

Brian Rasp

Phone: [857-215-2265](tel:8572152265)

Email: Brian_Rasp@DFCI.Harvard.edu

University of Virginia Health System

Recruiting

Charlottesville, Virginia, 22908, United States

Chrystal Axford

Phone: [804-683-2880](tel:804-683-2880)

Email: Cgp9e@hscmail.mcc.virginia.edu

Linda Duska, MD

Winship Cancer Institute of Emory University

Recruiting

Atlanta, Georgia, 30322-1013, United States

Adam Burgess

Phone: [404-712-9858](tel:404-712-9858)

Email: adam.burgess@emory.edu

R. Donald Harvey, MD

NYU Langone Medical Center - Laura and Isaac Perlmutter Cancer Center

Recruiting

New York, New York, 10016, United States

Salman Puneekar, MD

Stephen Cumberbatch

Phone: [407-517-8471](tel:407-517-8471)

Email: Stephen.Cumberbatch@nyulangone.org

South Texas Accelerated Research Therapeutics (Start) - Midwest Location

Recruiting

Grand Rapids, Michigan, 49546, United States

Nehal Lakhani, MD

Olivia Sweeney

Phone: [616-954-5554](tel:616-954-5554)

Email: olivia.sweeney@startmidwest.com

Yvette Cole

Phone: [616-954-5554](tel:616-954-5554)

Email: Yvette.Cole@startmidwest.com

Swedish Cancer Institute

Recruiting

Seattle, Washington, 98104, United States

Charles Drescher, MD

Chun-Fang Qiu

Phone: [206-215-6430](tel:206-215-6430)

Email: Chun-fang.Qiu@swedish.org

University of Chicago Medical Center

Recruiting

Chicago, Illinois, 60637, United States

Hedy Lee Kindler, MD

Iryna Kobrynets

Phone: [773-834-6421](tel:773-834-6421)

Email: Iryna.Kobrynets@bsd.uchicago.edu

Abramson Cancer Center of the University of Pennsylvania

Recruiting

Philadelphia, Pennsylvania, 19104, United States

Lainie Martin, MD

South Texas Accelerated Research Therapeutics

Recruiting

San Antonio, Texas, 78229, United States

Carrie Choi, RN

Phone: [210-593-2547](tel:210-593-2547)

Email: carrie.choi@startsa.com

Drew Rasco, MD

Karen McGee

Phone: [210-593-5270](tel:210-593-5270)

Email: karen.mcgee@startsa.com

Fred Hutchinson Cancer

Recruiting

Seattle, Washington, 98109-1023, United States

Elizabeth Liu

Phone: [206-606-7494](tel:206-606-7494)

Email: elizliu@seattlecca.org

Kalyan Banda, MD

Massachusetts General Hospital

Recruiting

Boston, Massachusetts, 02114, United States

Ryan Sullivan, MD

Terry Liu

Phone: [617-632-9250](tel:617-632-9250)

Email: TLIU32@mgh.harvard.edu

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Phone: [+41613241111](tel:+41613241111)

Email: novartis.email@novartis.com

Novartis Pharmaceuticals

Phone: [1-888-669-6682](tel:1-888-669-6682)

Email: novartis.email@novartis.com

Source URL: <https://prod1.novartis.com/clinicaltrials/study/nct04104776>

List of links present in page

1. <https://clinicaltrials.gov/ct2/show/NCT04104776>
2. [#trial-eligibility](#)
3. [tel:+33 \(556\) 333-282](tel:+33(556)333-282)
4. <mailto:l.wanner@bordeaux.unicancer.fr>
5. [tel:+33 \(0\) 2 40 16 56 98](tel:+33(0)240165698)
6. <mailto:helene.godet@chu-nantes.fr>
7. [tel:+33 \(0\) 240 08 40 30](tel:+33(0)240084030)
8. <mailto:tiphaie.chiron@chu-nantes.fr>
9. [tel:+33 \(0\) 2 53 48 22 43](tel:+33(0)253482243)
10. <mailto:claire.peluchon@chu-nantes.fr>

11. tel:+33 (0) 368767150
12. mailto:a.casper@icans.eu
13. tel:+33 (0) 3 20 29 56 38
14. mailto:s-chalal@o-lambret.fr
15. tel:+33 (0) 142 11 61 72
16. mailto:Mariem.LABIADH@gustaveroussy.fr
17. tel:+33 (0) 4 78 78 20 62
18. mailto:emilie.repetto@lyon.unicancer.fr
19. tel:39 051 214 3231
20. mailto:silvia.corazza3@unibo.it
21. tel:39 02 8224 5954
22. mailto:laura.paladini@cancercenter.humanitas.it
23. mailto:Federica.Mogavero@istitutotumori.mi.it
24. tel:+39 (029) 4372-183
25. mailto:Beatrice.Rizzoli@ieo.it
26. tel:+39 (06) 30158 545
27. mailto:giulia.ferrera@policlinicogemelli.it
28. tel:82-22-045-3855
29. mailto:ljh3531@amc.seoul.kr
30. tel:010-7583-3119
31. mailto:76344@ncc.re.kr
32. tel:8210-8737-0811
33. mailto:mnj2023sc@yuhs.ac
34. tel:82 (53) 258 6679
35. mailto:cjjs200400@gmail.com
36. tel:010-9266-2851
37. mailto:snu_sojeong@snu.ac.kr
38. tel:82-31-920-0859
39. mailto:76656@ncc.re.kr
40. tel:82 22-228-2759
41. mailto:HMJH24@yuhs.ac
42. tel:0048 792 206 646
43. mailto:grubiak.marta@gmail.com
44. tel:0048 22 546 2223
45. mailto:Anna.Pich@nio.gov.pl
46. tel:0048 574432284
47. mailto:kbalcerzak@ump.edu.pl
48. tel:0048 512 491 461
49. mailto:hubert.kondarewicz@pratia.com
50. tel:48 58 584 44 17
51. mailto:zspecht@uck.gda.pl
52. tel:+34 (91) 353 1920 Ext 7539
53. mailto:malemann@unav.es
54. tel:+34981950512/ +3498195567
55. mailto:cgarciamartinez.enf@gmail.com
56. tel:+34 871 20 61 30
57. mailto:noemi.ceron@ssib.es
58. tel:+34 (696) 635-551
59. mailto:montse.oncologiahuvr@gmail.com
60. tel:(+34)93 274 60 00 4691
61. mailto:ameire@vhio.net
62. tel:+34 93 274 60 00
63. mailto:ameire@vhio.net
64. tel:+34 (948) 255 400 Ext 2733
65. mailto:megana@unav.es
66. tel:+34 913908626
67. mailto:ipascualsr.imas12@h12o.es
68. tel:+34 663224865
69. mailto:datamanager3@fincivo.org

70. tel:+34 (923) 291 316
71. mailto:mdelgadocri@saludcastillayleon.es
72. tel:+34 914521900 (ext. 38901)
73. mailto:rsanchez@nextoncology.eu
74. tel:+34 972 75 49 53
75. mailto:nmartin@iconcologia.net
76. tel:01225 824288
77. mailto:samantha.curtis@nhs.net
78. tel:442031865362
79. mailto:Fiona.Williams@rmh.nhs.uk
80. tel:0116 258 7598
81. mailto:sarah.porter@uhl-tr.nhs.uk
82. tel:01823 342582
83. mailto:Tamlyn.Russell@SomersetFT.nhs.uk
84. tel:0208 383 1366
85. mailto:lauren.holt9@nhs.net
86. tel:551-996-8170
87. mailto:Celina.Joco@hmn.org
88. tel:857-215-2265
89. mailto:Brian_Rasp@DFCI.Harvard.edu
90. tel:804-683-2880
91. mailto:Cgp9e@hscmail.mcc.virginia.edu
92. tel:404-712-9858
93. mailto:adam.burgess@emory.edu
94. tel:407-517-8471
95. mailto:Stephen.Cumberbatch@nyulangone.org
96. tel:616-954-5554
97. mailto:olivia.sweeney@startmidwest.com
98. tel:616-954-5554
99. mailto:Yvette.Cole@startmidwest.com
100. tel:206-215-6430
101. mailto:Chun-fang.Qiu@swedish.org
102. tel:773-834-6421
103. mailto:Iryna.Kobrynets@bsd.uchicago.edu
104. tel:210-593-2547
105. mailto:carrie.choi@startsa.com
106. tel:210-593-5270
107. mailto:karen.mcgee@startsa.com
108. tel:206-606-7494
109. mailto:elizliu@seattlecca.org
110. tel:617-632-9250
111. mailto:TLIU32@mgh.harvard.edu
112. tel:+41613241111
113. mailto:novartis.email@novartis.com
114. tel:1-888-669-6682
115. mailto:novartis.email@novartis.com